Genomic Health (NASDAQ:GHDX) updated its FY 2018 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.03-1.08 for the period, compared to the Thomson Reuters consensus estimate of $0.53. The company issued revenue guidance of $389-391 million, compared to the consensus revenue estimate of $380.91 million.Genomic Health also updated its FY18 guidance to $1.03-$1.08 EPS.
Several equities analysts have weighed in on the company. Piper Jaffray Companies reissued a hold rating and issued a $60.00 target price on shares of Genomic Health in a research note on Friday, August 3rd. Jefferies Financial Group reissued a hold rating and issued a $50.00 target price on shares of Genomic Health in a research note on Friday, August 3rd. BidaskClub lowered Genomic Health from a strong-buy rating to a buy rating in a research note on Thursday, October 4th. Zacks Investment Research lowered Genomic Health from a buy rating to a hold rating in a research note on Tuesday, August 7th. Finally, TheStreet raised Genomic Health from a c rating to a b- rating in a research note on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, two have given a buy rating and two have given a strong buy rating to the company’s stock. Genomic Health presently has an average rating of Hold and a consensus target price of $48.33.
NASDAQ:GHDX traded up $19.39 during mid-day trading on Wednesday, hitting $90.18. The company had a trading volume of 914,871 shares, compared to its average volume of 268,878. Genomic Health has a fifty-two week low of $26.54 and a fifty-two week high of $92.18. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of 9,018.00 and a beta of 0.44.
In other Genomic Health news, insider Frederic Pla sold 5,500 shares of the stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $55.93, for a total value of $307,615.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $61.51, for a total value of $507,457.50. Following the completion of the sale, the director now owns 75,572 shares of the company’s stock, valued at $4,648,433.72. The disclosure for this sale can be found here. Insiders sold 199,279 shares of company stock valued at $12,083,105 over the last 90 days. Corporate insiders own 45.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Genomic Health (GHDX) Releases FY 2018 Earnings Guidance” was first posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.wkrb13.com/2018/11/08/genomic-health-ghdx-releases-fy-2018-earnings-guidance.html.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Further Reading: Return on Equity (ROE)
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.